Optical imaging predicts tumor response to anti-EGFR therapy.
about
Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targetsOptical metabolic imaging of treatment response in human head and neck squamous cell carcinomaAdvancing Molecular-Guided Surgery through probe development and testing in a moderate cost evaluation pipelineSteroid Receptor Coactivator-3 (SRC-3/AIB1) as a Novel Therapeutic Target in Triple Negative Breast Cancer and Its Inhibition with a Phospho-Bufalin Prodrug.Evaluation of tyrosine receptor kinases in the interactions of head and neck squamous cell carcinoma cells and fibroblasts.Polychromatic in vivo imaging of multiple targets using visible and near infrared light.Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo.Normalization of TAM post-receptor signaling reveals a cell invasive signature for Axl tyrosine kinase.In vivo tomographic imaging with fluorescence and MRI using tumor-targeted dual-labeled nanoparticles.Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma.Molecular imaging in gastroenterology.Toxicity and Pharmacokinetic Profile for Single-Dose Injection of ABY-029: a Fluorescent Anti-EGFR Synthetic Affibody Molecule for Human Use.Advancing theranostics with tumor-targeting peptides for precision otolaryngology.
P2860
Q26830569-C4CDA732-14DD-4579-8D23-1FEF1FEC6CD0Q28540413-31F6B9F6-9A3F-4910-8E49-A8D0BE4F5E15Q35518032-B129162D-0E3C-49EF-827D-8FC90B37EA79Q35796826-64955152-8E25-48BC-8201-0A2993660745Q36395148-20162AF1-9D8C-4BCB-A0F7-55E57C642DB8Q36902111-7B16ECA0-06FD-4382-A709-42A61CEAC752Q37226145-7BB5F9AD-E8EF-4FE9-9145-E1FAD7A30021Q37233198-9D36A276-3856-4835-86B2-52D3B06E890EQ37407505-DE8F0EB5-612B-46FF-AC5A-2AB2F1F4136BQ37633071-6E4328C3-1FC7-4AEE-A8E2-341CC5256510Q38121747-03B628EB-109E-4A6C-BAFF-C97B5FF06264Q47928453-2149AACA-F5CB-4998-A618-764923595477Q55006457-98E14F95-F10F-4C5A-8F3B-5DBDA943D99D
P2860
Optical imaging predicts tumor response to anti-EGFR therapy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Optical imaging predicts tumor response to anti-EGFR therapy.
@ast
Optical imaging predicts tumor response to anti-EGFR therapy.
@en
Optical imaging predicts tumor response to anti-EGFR therapy.
@nl
type
label
Optical imaging predicts tumor response to anti-EGFR therapy.
@ast
Optical imaging predicts tumor response to anti-EGFR therapy.
@en
Optical imaging predicts tumor response to anti-EGFR therapy.
@nl
prefLabel
Optical imaging predicts tumor response to anti-EGFR therapy.
@ast
Optical imaging predicts tumor response to anti-EGFR therapy.
@en
Optical imaging predicts tumor response to anti-EGFR therapy.
@nl
P2093
P2860
P356
P1476
Optical imaging predicts tumor response to anti-EGFR therapy.
@en
P2093
Eben L Rosenthal
Emily E Helman
J Robert Newman
Kurt R Zinn
Nichole R Dean
Wenyue Zhang
P2860
P304
P356
10.4161/CBT.10.2.12164
P577
2010-07-01T00:00:00Z